Luoxin Pharmaceutical joins hands with Jointown to focus on the safety of children's medication in China and build a new pattern of healthy development

On October 23, 2021, Luoxin Pharmaceutical Group Co.
, Ltd.
(referred to as "Luoxin Pharmaceutical") and Jointown Pharmaceutical Group Co.
, Ltd.
(referred to as The National Pediatrics Academic Conference was signed at the same time.
Experts, scholars and business representatives dedicated to the pediatrics industry gathered in Wuhan to make concerted efforts to jointly promote the high-quality development of pediatrics in China
.

Cheng Botao, Secretary General of Hubei Pharmaceutical Industry Association, Professor Luo Xiaoping, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Professor Xu Baoping, Beijing Children's Hospital Affiliated to Capital Medical University, Liu Dengpan, Vice Chairman of Jointown, Liu Zhenteng, Chairman and CEO of Luoxin Pharmaceutical, Dong Lijun, chief operating officer and executive vice president of Luoxin Pharmaceutical, and other relevant leaders and guests attended the strategic cooperation site
.

Cheng Botao, Secretary-General of Hubei Pharmaceutical Industry Association, delivered a speech.
He pointed out that the pharmaceutical industry is an important industry related to the national economy and people's livelihood, and is an important guarantee for promoting the construction of a healthy China
.

Speech by Cheng Botao, Secretary General of Hubei Pharmaceutical Industry Association

Professor Luo Xiaoping from Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology said in his speech: “As pediatricians in China, we are well aware of the importance of children’s health to the country.
Taking care of children’s healthy growth not only requires us to achieve and strengthen the standardization of pediatric diseases.
Diagnosis and treatment must also build a strong medical security system
.

Speech by Professor Luo Xiaoping from Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology

Professor Xu Baoping, director of the Respiratory Department of Beijing Children’s Hospital affiliated to Capital Medical University, said: “Today I am very happy to see Luoxin Pharmaceuticals and Jointown Pharmaceuticals work together to develop the cause of children’s health
.

Professor Xu Baoping, Director of Respiratory Department, Beijing Children's Hospital, Capital Medical University

Subsequently, the strategic cooperation parties formally signed the agreement
.

Photos of the signing ceremony between the two parties

It is understood that in August this year, China's first ambroxol hydrochloride spray, Luo Runchang®, was officially approved for marketing
.

Liu Dengpan, Vice Chairman of Jointown, said: “It is exciting news to learn that Luoxin Pharmaceutical’s special medicine for children developed by Luoxin Pharmaceutical for the characteristics of children’s respiratory diseases has been approved by the state
.

Liu Dengpan, Vice Chairman of Jointown

Liu Zhenteng, Chairman and CEO of Luoxin Pharmaceutical, expressed his welcome and thanks to all the guests attending the meeting.
He said: "We are very pleased to establish a strategic partnership with
Jointown.

Liu Zhenteng, Chairman and CEO of Luoxin Pharmaceutical

About Jointown

Jointown Pharmaceutical Group Co.
, Ltd.
is a technology-driven full-chain pharmaceutical supply chain service-oriented enterprise.
The company is based in the major health industries such as pharmaceutical circulation, logistics services, and medical health.
Its main business includes pharmaceutical distribution and supply chain services, total There are five major areas: agency general sales and industrial self-production, digital retail, digital logistics and supply chain solutions, medical health and technology value-added services
.

About Luoxin Pharmaceutical

Luoxin Pharmaceutical Group Co.
, Ltd.
(referred to as "Luoxin Pharmaceutical", 002793.
SZ) is a large-scale pharmaceutical enterprise group integrating drug research and development, production, trade and medical and health services.
It was founded in 1988 and is located in Shandong, China.
, Shanghai, Chengdu and other places have established R&D and production bases with more than 6,000 employees
.
With the mission of "delivering health", Luoxin Pharmaceutical focuses on solving unmet clinical needs in the fields of digestion, breathing, and anti-tumor diseases, and improving the availability of medicines and medical and health services
.

Luoxin Pharmaceutical has launched a rich and competitive product portfolio, and its core products are in a leading position in the market for drugs for digestive and respiratory diseases
.
Many of the company's products have been included in the "National Key New Product Plan", "National Torch Plan", "Major New Drug Creation" and other major scientific and technological projects
.
Since 2006, the company has continuously entered China's top 100 pharmaceutical companies.
Since 2011, it has been continuously rated as the best industrial enterprise in China's pharmaceutical R&D product line.
It is a national key high-tech enterprise, a national technological innovation demonstration enterprise, and a national industrial quality benchmarking enterprise.
, Has repeatedly won the second prize of National Science and Technology Progress Award
.

For more information, please visit